News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Massachusetts Biotechnology Council, Inc. Release: Massachusetts Companies Collect $129 million in Grants and Credits

11/5/2010 1:06:23 PM

November 4, 2010 (Cambridge, MA)— MassBio President and CEO Robert K. Coughlin congratulated the more than 300 Massachusetts biotechnology companies named as recipients of the new Therapeutic Discovery Project grants or tax credits. The announcement was made by U.S. Treasury Secretary Geithner and Health and Human Services Secretary Sebelius yesterday.

“As this announcement illustrates, the Therapeutic Discovery Project Credit program ensures Massachusetts’ most cutting-edge companies will be able to maintain their commitment to investment in life-saving research,” said Coughlin said. “The program helps biotech companies continue to discover new cures and therapies to solve unmet medical needs, while adding good jobs across the Commonwealth. We are thrilled to see this investment being made and congratulate all of the recipients.”

The $1 billion Qualifying Therapeutic Discovery Project Credit program was included in the Affordable Care Act signed into law in March. The program, which was limited to companies with fewer than 250 employees, was championed in the Senate by Massachusetts Senator John Kerry and supported by the entire Massachusetts legislative delegation. A total of 310 Massachusetts companies were awarded either a tax credit or grants under the program, for a total of almost $129 million in investment.

MassBio member companies receiving awards include:

Acceleron Pharma Acetylon Pharmaceutical Acusphere, Inc.

AdvanDx Inc. Agios Pharmaceuticals Aileron Therapeutics Alfama, Inc. Alnylam Pharmaceuticals Anchor Therapeutics Antigen Express Antigenics, Inc. Antisoma Aphios Corporation Archemix Corp. ARIAD Pharmaceuticals Arietis Corporation Arisaph Pharmaceuticals Arqule Inc. Arsenal Medical, Inc. Artisan Pharma AVEO Pharmaceuticals Avila Therapeutics Bach Pharma BG Medicine, Inc. BIND Biosciences BioScale, Inc. BioVex, Inc. Boston Biomedical Catabasis Pharmaceuticals Celexion LLC Celidex Therapeutics CellThera, Inc. Cerulean Pharma Concert Pharma Constellation Pharma Creagen Biosciences, Inc. Curis, Inc. Cytonome/ST Dicerna Pharmaceuticals Differential Proteomics Dyax Corp Edimer Pharmaceuticals Eleven Biotherapeutics Enanta Pharmaceuticals Entra Pharmaceuticals Epizyme Inc. ETEX Corporation Eutropics Pharmaceuticals Excelimmune Inc. Eyegate Pharmaceuticals Flexion Therapeutics FoldRx Pharmaceuticals Forma Therapeutics Formatech Inc. Galenea Corp. Genetix Pharmaceuticals Genocea Biosciences, Inc. GL Synthesis Inc. Helicos BioSciences Hybrid Silica Technologies Hydra Biosciences ImmunoGen Infinity Discovery, Inc. Inotex Pharmaceuticals Intelect Medical, Inc. Intelligent Bio-Systems IntelligentMDx Interleukin Genetics InVivo Therapeutics Ironwood Pharma Kala Pharmaceuticals Link Medicine Corporation Logical Therapeutics Mercury Therapeutics Merrimack Pharmaceuticals Mersana Therapeutics Metamark Genetics Microbiotix MicroCHIPS Modular Genetics, Inc. Momenta Pharmaceuticals NKT Therapeutics NormOxys, Inc. Ocular Therapeutix On-Q-Ity, Inc. OPK Biotech Paratek Pharmaceuticals Peptimmune, Inc. Pervasis Therapeutics Pharmalucence, Inc. Predictive Biosciences PrimeraDx, Inc. Pro-Pharmaceuticals, Inc. Proteon Therapeutics Pulmatrix Inc. Quanterix Corporation Radius Health, Inc. Rapid Micro Biosystems Repligen Corporation Resolvyx Pharma Rxi Pharmaceuticals Satori Pharmaceuticals Seahorse Bioscience Seaside Therapeutics Selecta Biosciences SelectX Pharma Semprus BioSciences Seventh Sense Biosystems SmartCells, Inc. Strategic Science & Technologies Stromedix, Inc. Surface Logix, Inc. Synageva BioPharma Corp Syndax Pharma SynDevRX, Inc. Syndexa Pharmaceuticals Synta Pharmaceuticals T2 Biosystems, Inc. Taligen Therapeutics, Inc. Tepha Inc. Tetraphase Pharmaceuticals Tolerx, Inc. Velico Medical, Inc. Verax Biomedical Inc. Virdante Pharmaceuticals Visterra, Inc. ZIOPHARM Oncology, Inc.

MassBio can arrange interview with awardees.

The list of Massachusetts companies, projects and grant or credit amounts is available online here. For a full list of the awards nationwide, go to the IRS website.

The Massachusetts Biotechnology Council

The Massachusetts Biotechnology Council (MassBio), a not-for-profit organization that represents and provides services and support for the Massachusetts biotechnology industry, is the nation’s oldest biotechnology trade association. Founded in 1985, MassBio is committed to advancing the development of critical new science, technology and medicines that benefit people worldwide. Representing over 600 biotechnology companies, academic institutions, research hospitals, and service organizations involved in life sciences and health care, MassBio works to advance policy and promote education, while providing member programs and events, industry information, and services.

Sarah MacDonald Director of Communications Massachusetts Biotechnology Council One Cambridge Center, Ninth Floor Cambridge, MA 02142 e: p: +1 (617) 674-5115 f: 617-674-5101

Read at

comments powered by Disqus